Shares of Proteostasis Therapeutics Inc (NASDAQ:PTI) saw unusually-high trading volume on Friday . Approximately 989,500 shares traded hands during mid-day trading, a decline of 23% from the previous session’s volume of 1,278,783 shares.The stock last traded at $0.97 and had previously closed at $0.91.
PTI has been the topic of several research reports. HC Wainwright reaffirmed a “buy” rating on shares of Proteostasis Therapeutics in a report on Friday, August 9th. ValuEngine raised Proteostasis Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Zacks Investment Research cut Proteostasis Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, July 26th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. Proteostasis Therapeutics presently has an average rating of “Hold” and a consensus target price of $8.75.
The company has a quick ratio of 8.19, a current ratio of 8.19 and a debt-to-equity ratio of 0.15. The company has a fifty day moving average price of $0.76 and a 200-day moving average price of $1.45. The stock has a market capitalization of $49.60 million, a P/E ratio of -0.60 and a beta of -0.59.
Proteostasis Therapeutics (NASDAQ:PTI) last issued its earnings results on Wednesday, August 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.01). As a group, research analysts expect that Proteostasis Therapeutics Inc will post -1.49 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of PTI. Paloma Partners Management Co bought a new stake in Proteostasis Therapeutics during the second quarter worth approximately $150,000. Bank of America Corp DE grew its stake in shares of Proteostasis Therapeutics by 2,174.2% during the fourth quarter. Bank of America Corp DE now owns 49,510 shares of the company’s stock valued at $160,000 after buying an additional 47,333 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Proteostasis Therapeutics by 445.5% during the second quarter. Jane Street Group LLC now owns 175,050 shares of the company’s stock valued at $171,000 after buying an additional 142,958 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of Proteostasis Therapeutics during the second quarter valued at approximately $178,000. Finally, A.R.T. Advisors LLC bought a new position in shares of Proteostasis Therapeutics during the second quarter valued at approximately $189,000. 44.64% of the stock is currently owned by institutional investors.
About Proteostasis Therapeutics (NASDAQ:PTI)
Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company's lead product candidates include cystic fibrosis transmembrane conductance regulator (CFTR) modulators comprising PTI-428, an amplifier, which has completed Phase II study; and PTI-801, a third generation corrector molecule and PTI-808, a potentiator molecule, which has completed Phase I study.
Featured Article: Limitations of analyzing profit margin
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.